Validated a tool that assesses the risk of sudden death due to a heart disease

  • Twenty-nine reference centers from the United States, Canada, the Netherlands, Italy, France, and Spain, including IDIBELL, have participated in an international multicenter study that validated a model for predicting the risk of ventricular arrhythmias and sudden death in arrhythmogenic cardiomyopathy of the right ventricle (ARVC).
  • This calculator can be used as a guide for making relevant clinical decisions and is free to use by accessing the website.
NO080 - A di Marco_M subita - Imatge

The results of the calculator validation study have been published in the European Heart Journal. Among the co-authors is Dr. Andrea Di Marco, a postdoctoral researcher in the IDIBELL cardiovascular diseases group and associate physician in the Arrhythmia Unit of the HUB Cardiology Service.

We offered an important contribution to obtain such a large sample of patients, something quite exceptional since it is a relatively rare disease,” explained Di Marco.

ARVC is a type of genetically based cardiomyopathy characterized by dysfunction of the right ventricle, although the involvement of both ventricles is increasingly recognized. It is also characterized by the presence of life-threatening ventricular arrhythmias, sudden death could be the first manifestation of the disease.

External validation confirms that the evaluated model has a good predictive capacity for ventricular arrhythmias and sudden death. Therefore, “the ARVCrisk calculator can be used as a guide for making relevant clinical decisions, such as the implantation of a cardioverter-defibrillator (ICD) for primary prevention in patients with ARVC,” says Dr. Di Marco.

In parallel, the IDIBELL team has actively collaborated in the preparation and execution of another project with the same cohort of patients, currently in the statistical analysis phase.



The Bellvitge Biomedical Research Institute (IDIBELL) is a biomedical research center created in 2004. It is participated by the Bellvitge University Hospital and the Viladecans Hospital of the Catalan Institute of Health, the Catalan Institute of Oncology, the University of Barcelona and the City Council of L’Hospitalet de Llobregat.

IDIBELL is a member of the Campus of International Excellence of the University of Barcelona HUBc and is part of the CERCA institution of the Generalitat de Catalunya. In 2009 it became one of the first five Spanish research centers accredited as a health research institute by the Carlos III Health Institute. In addition, it is part of the “HR Excellence in Research” program of the European Union and is a member of EATRIS and REGIC. Since 2018, IDIBELL has been an Accredited Center of the AECC Scientific Foundation (FCAECC).

Scroll to Top